ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,770.20
0.55%
Dow Jones
42,801.72
0.52%
US Dollar vs MXN
20.26717
0.00%
Brent Oil
70.235
0.00%
Bitcoin
82,555.43
-4.19%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Taysha Gene Therapies Inc (TSHA) Cotización

Taysha Gene Therapies Inc

Taysha Gene Therapies Inc (TSHA)

NASDAQ
1.75
0.06
(3.55%)
Cerrado 09 Marzo 2:00PM
Delayed by 15 minutes
1.755
0.005
(0.29%)
Fuera de horario: 6:59PM
Delayed by 15 minutes
Gráfico avanzado

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
1.75
Postura de Compra
1.39
Postura de Venta
3.98
Volume Operado de la Acción
1,136,032
1.66 Rango del Día 1.765
1.19 Rango de 52 semanas 4.32
Capitalización de Mercado [m]
358.753M
Precio Anterior
1.69
Precio de Apertura
1.68
Hora
1
@
1.75
Última hora de negociación
Volumen financiero
US$ 1,967,211
Precio Promedio Ponderado
1.7317
Volumen promedio (3 m)
2,164,531
Acciones en circulación
205,001,632
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-3.22
Beneficio por acción (BPA)
-0.54
turnover
15.45M
Beneficio neto
-111.57M

Acerca de Taysha Gene Therapies Inc

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and com... Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.tayshagtx.com
Sede
Dover, Delaware, USA
Fundado
-
Taysha Gene Therapies Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TSHA. The last closing price for Taysha Gene Therapies was US$1.69. Over the last year, Taysha Gene Therapies shares have traded in a share price range of US$ 1.19 to US$ 4.32.

Taysha Gene Therapies currently has 205,001,632 shares in issue. The market capitalisation of Taysha Gene Therapies is US$346.45 million. Taysha Gene Therapies has a price to earnings ratio (PE ratio) of -3.22.

TSHA Últimas noticias

Más noticias

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
26 Febrero 2025
TSHA (3.55%)

Form 8-K - Current report
Edgar (US Regulatory)
26 Febrero 2025
TSHA (3.55%)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
05 Febrero 2025
TSHA (3.55%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
07 Enero 2025
TSHA (3.55%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
22 Diciembre 2024
TSHA (3.55%)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.159.3751.61.771.5716291991.64511287CS
40.052.941176470591.71.8851.4618857031.65991649CS
12-0.5-22.22222222222.252.261.43521645311.7207234CS
26-0.31-15.04854368932.063.311.1931807362.02452665CS
52-1.005-36.47912885662.7554.321.1927807422.32742093CS
156-3.91-69.08127208485.667.07740.519831362.30517287CS
260-20.5-92.134831460722.2533.840.513832552.91010142CS

TSHA - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Taysha Gene Therapies?
El precio actual de las acciones de Taysha Gene Therapies es US$ 1.75
¿Cuántas acciones de Taysha Gene Therapies están en circulación?
Taysha Gene Therapies tiene 205,001,632 acciones en circulación
¿Cuál es la capitalización de mercado de Taysha Gene Therapies?
La capitalización de mercado de Taysha Gene Therapies es USD 346.45M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Taysha Gene Therapies?
Taysha Gene Therapies ha negociado en un rango de US$ 1.19 a US$ 4.32 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Taysha Gene Therapies?
El ratio precio/beneficio de Taysha Gene Therapies es -3.22
¿Cuál es el ratio de efectivo a ventas de Taysha Gene Therapies?
El ratio de efectivo a ventas de Taysha Gene Therapies es 23.21
¿Cuál es la moneda de reporte de Taysha Gene Therapies?
Taysha Gene Therapies presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Taysha Gene Therapies?
El último ingresos anual de Taysha Gene Therapies es USD 15.45M
¿Cuál es el último beneficio anual de Taysha Gene Therapies?
El último beneficio anual de Taysha Gene Therapies es USD -111.57M
¿Cuál es la dirección registrada de Taysha Gene Therapies?
La dirección registrada de Taysha Gene Therapies es 108 LAKELAND AVE, DOVER, DELAWARE, 19901
¿Cuál es la dirección del sitio web de Taysha Gene Therapies?
La dirección del sitio web de Taysha Gene Therapies es www.tayshagtx.com
¿En qué sector industrial opera Taysha Gene Therapies?
Taysha Gene Therapies opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
US$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
143.04M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
142.23M

TSHA Finanzas

Finanzas

TSHA Discussion

Ver más
georgie18 georgie18 2 meses hace
TSHA...$1.53... 🥳... https://finviz.com/insidertrading.ashx?oc=1494695&tc=7 ...Bullish Harami Cross Reversal Pattern...
👍️0
glenn1919 glenn1919 3 meses hace
tsha..........................https://stockcharts.com/h-sc/ui?s=tsha&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 meses hace
TSHA, under $2

👍️0
glenn1919 glenn1919 3 meses hace
TSHA.....................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 meses hace
TSHA..............https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 4 meses hace
TSHA...$2.58...Off the $2.10 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 85

Tuesday, November 12, 2024 3:56:56 PM

Post#
89
of 90
TSHA...$2.41...🥳...on the $2.10 gapper alert...All out for now...will revisit...

georgie18

Member Level
Re: None

Monday, November 11, 2024 5:18:23 PM

Post#
664504
of 664675
TSHA...$2.10... https://schrts.co/KsMDABsM ...Psar flipped Bullish...🥳Should be a gapper in the morning...
👍️0
glenn1919 glenn1919 4 meses hace
TSHA............................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 4 meses hace
TSHA...$2.41...🥳...on the $2.10 gapper alert...All out for now...will revisit...

georgie18

Member Level
Re: None

Monday, November 11, 2024 5:18:23 PM

Post#
664504
of 664675
TSHA...$2.10... https://schrts.co/KsMDABsM ...Psar flipped Bullish...🥳Should be a gapper in the morning...
👍️0
zendeli1 zendeli1 4 meses hace
restart soon
👍️0
glenn1919 glenn1919 4 meses hace
TSHA....................................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 meses hace
TSHA.................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 4 meses hace
TSHA...$2.10... https://schrts.co/KsMDABsM ...Psar flipped Bullish...🥳Should be a gapper in the morning...
👍️0
nsomniyak nsomniyak 4 meses hace
I sent an email to TSHA IR on 11/5 asking if they could explain the sharp drop (at that time) and high volume in the stock. I did not receive an answer.
👍️0
nsomniyak nsomniyak 4 meses hace
Premiums were high all last week and today on TSHA call options. Volume in the common has been high as well.
👍️0
Pip611 Pip611 4 meses hace
I was thinking the same thing, it started to pop in the afternoon and now it took off after hours
👍️0
nsomniyak nsomniyak 4 meses hace
What is going on with TSHA in the AH today? Up sharply - now 2.10
👍️0
Monksdream Monksdream 5 meses hace
TSHA under $3
👍️0
Monksdream Monksdream 7 meses hace
TSHA under $3
👍️0
TechandBio TechandBio 8 meses hace
Started buying shares last year at .77 Riding the houses money now and sold three quarters of my shares at $4.00 range when I saw the double top formation come into play I can see this going to $8.00-$10.00 only on a buyout in the next year. Risky with only a handful of patients dosed and the competition for Rhett but a cunning bet with the management at TSHA. now.
CEO and CMO are best in class. Not a core position but glad I'm in with a few. I hope they have a remedy for these poor kids with Rhett.

$TSHA
👍️0
nsomniyak nsomniyak 8 meses hace
If these are senior people in prominent management or technical roles it is pretty standard for them to be granted options as part of their compensation package. They vest over 4 years, so it is not an outright giveaway.

Additionally, since these are NEW employees, by definition they have not manipulated the stock down to get a lower option strike price.

I am fine with this very normal comp package.
👍️ 1
ErnieBilco ErnieBilco 8 meses hace
I'm sorry but granting options to NEW employees is absurd - they shouldn't be entitled to stock options UNTIL their one year on the job.

No wonder why this has trouble making gains for shareholders whom the employees actually work for.
👍️0
LegendaryNomad22 LegendaryNomad22 9 meses hace
Weird. Both TSHA and NGNE have gene therapy candidates for Rett and both of them tanked today, despite sharing strong interim results. There's an International Rett Syndrome Foundation meeting today and tomorrow, so I wonder if something happened there to take the wind out of the gene therapy treatment class. Anyone have any knowledge here?
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
Diluted on news
👍️0
Pip611 Pip611 9 meses hace
Ouch - what happen?
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
TSHA...GAPPING
👍️0
Tiger Money Tiger Money 9 meses hace
Yes, no sorry, didn’t mean to imply that. I was asking if you have other bio names you have on your radar (obviously know about this and Huma). Thanks
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
chart has nothing to do with what sector!!
👍️0
Tiger Money Tiger Money 9 meses hace
You have the bios nailed down! Any I should put on my radar? As always, thank you as I sincerely appreciate your help and knowledge. Thanks!
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
TSHA BREAK OUT
👍️0
Monksdream Monksdream 9 meses hace
TSHA new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
TSHA...HERES 4 DOLLA
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
TSHA...READY FOR 4
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
TSHA...BIO BEAST BREAKING HEWRE CHAINS
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
TSHA HERE WE GO ON THE BREAK OUT!!
👍️0
glenn1919 glenn1919 9 meses hace
TSHA......................................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
TSHA HERE COMES THE BREAK
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
TSHA...NEXT BIO READY TO BEAST!
👍️0
FooBarAndGrill FooBarAndGrill 9 meses hace
Taysha may have the real ONE-SHOT genetic cure. It may REALLY work.
Good luck getting any health insurance plan to list this $Million dollar shot in their drug formulary.
👍️0
Monksdream Monksdream 9 meses hace
TSHA under $5
👍️0
glenn1919 glenn1919 12 meses hace
TSHA..............................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 12 meses hace
TSHA..READY TO PUSH TO 4.00
👍️0
TrendTrade2016 TrendTrade2016 12 meses hace
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 12 meses hace
TSHA...HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 1 año hace
TSHA..here we go
👍️0
TrendTrade2016 TrendTrade2016 1 año hace
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 1 año hace
TSHA NEXT BIO BEAST TO RUN TO 3.61 WATCH THE MAGIC
👍️0
FooBarAndGrill FooBarAndGrill 1 año hace
“Dosing the first pediatric patient with Rett syndrome marks an important step forward in our efforts to broaden the clinical evaluation of TSHA-102 to younger patients with earlier stages of Rett syndrome. We are pleased with our progress on expanding the study of TSHA-102 across a broad population of ages and stages of Rett syndrome to bring a potentially transformative treatment option to all patients and families suffering from this devastating disease,” said Sukumar Nagendran, M.D., President, and Head of R&D of Taysha. “The pediatric trial will build on our ongoing REVEAL adolescent and adult trial, where early data demonstrated improvements across multiple clinical domains in adult patients with the most advanced stage of disease. We also plan to expand our U.S. pediatric trial into the U.K. following the recent acceptance of our CTA by the MHRA.”
👍️0
FooBarAndGrill FooBarAndGrill 1 año hace
Estimated Enrollment : 18 participants
(was 12).
https://classic.clinicaltrials.gov/ct2/show/NCT05606614
👍️0
FooBarAndGrill FooBarAndGrill 1 año hace
“Following review of the initial clinical data from the first two adult patients treated with TSHA-102 and Chemistry, Manufacturing, and Controls (CMC) data, Health Canada has authorized our protocol amendment to include adolescent patients aged 12 years and older in the ongoing REVEAL Phase 1/2 adult trial,”
https://ih.advfn.com/stock-market/NASDAQ/taysha-gene-therapies-TSHA/stock-news/92678004/taysha-gene-therapies-announces-expanded-eligibili
👍️0
FooBarAndGrill FooBarAndGrill 1 año hace
The P1 TSHA-102 REVEAL Adult Study has been on a slow boat.
Hopefully, the Clinical Updates PR will give the push to finally complete enrollment of the 12 adult female Rett patients needed for the trial.
I'm guessing reluctance to enroll has been based on the one-time injection into the intrathecal space (directly into the Cerebral Spinal Fluid).
It's definitely worth the risk, IMO. Good Luck to All.
👍️0

Su Consulta Reciente

NASDAQ
TSHA
Taysha Gene Therapies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios